TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38506917

Group type: EXPERIMENTAL
Intervention: IMPACT+TAU
Number of subjects: 160

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 160
Study: 38507025

Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cricoid pressure
Number of subjects: 76
Study: 38507100

Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Number of subjects: 280
Study: 38507109

Group type: EXPERIMENTAL
Intervention: dURS with biopsy
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: High-grade biopsy
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Ureteroscopic low-grade tumours
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Ureteroscopic staging
Number of subjects: 2380

Group type: EXPERIMENTAL
Intervention: Cytology outcomes
Number of subjects: 2380
Study: 38507441

Group type: EXPERIMENTAL
Intervention: Full MCP (curriculum-activated social network interactions)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Basic MCP (educational sessions with organic social network interactions)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Full MCP
Number of subjects: 914

Group type: COMPARATOR
Intervention: Control (standard care with active monitoring and screenings)
Number of subjects: 914
Study: 38507476

Group type: EXPERIMENTAL
Intervention: CNS-active potentially inappropriate medication (PIM)
Number of subjects: 8031

Group type: EXPERIMENTAL
Intervention: Potential subadequate antidepressant dosing
Number of subjects: 8031

Group type: COMPARATOR
Intervention: CNS-active PIMs
Number of subjects: 8031
Study: 38507607

Group type: EXPERIMENTAL
Intervention: Chronic altitude exposure
Number of subjects: 0
Study: 38507662

Group type: EXPERIMENTAL
Intervention: Reduced-volume irradiation of uninvolved neck
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38507688

Group type: EXPERIMENTAL
Intervention: Enasidenib plus azacitidine
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Enasidenib plus chemotherapy
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Baseline risk factors
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Overall management of DS
Number of subjects: 643
Study: 38507692

Group type: EXPERIMENTAL
Intervention: Yogic breathing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow breathing
Number of subjects: 0
Study: 38507751

Group type: EXPERIMENTAL
Intervention: Ribociclib plus NSAI (letrozole or anastrozole)
Number of subjects: 426

Group type: COMPARATOR
Intervention: NSAI alone
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Ribociclib plus NSAI
Number of subjects: 426
Study: 38507752

Group type: EXPERIMENTAL
Intervention: scAAV9/JeT-GAN (a self-complementary adeno-associated virus-based gene therapy)
Number of subjects: 14
Study: 38507879

Group type: EXPERIMENTAL
Intervention: Virtual Rainforest (VRF) application
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: White Noise (WN) application
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 38507976

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Effective Apnea Hypopnea Index (eAHI)
Number of subjects: 169
Study: 38507987

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 218

Group type: COMPARATOR
Intervention: Symptom deterioration trajectory
Number of subjects: 218
Study: 38508135

Group type: EXPERIMENTAL
Intervention: KN046 plus chemotherapy (pemetrexed for non-sq-NSCLC and paclitaxel plus carboplatin for sq-NSCLC)
Number of subjects: 0
Study: 38508239

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for NSCLC
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for breast cancer (BC)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for colorectal cancer (CRC)
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) for prostate cancer (PC)
Number of subjects: 999
Study: 38508334

Group type: EXPERIMENTAL
Intervention: REVEAL Lite 2 risk score
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: REVEAL 2.0 risk score
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: European Society of Cardiology/European Respiratory Society 2022 risk score
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: COMPERA 3-strata risk score
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: COMPERA 4-strata risk score
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: REVEAL scores as continuous prediction models
Number of subjects: 8565

Group type: EXPERIMENTAL
Intervention: Various subgroups analysis
Number of subjects: 8565
Study: 38508589

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided cervical medial branch blocks (USG CMBB)
Number of subjects: 500
Study: 38508632

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study: 38508633

Group type: EXPERIMENTAL
Intervention: Text messaging (TM) with chatbot or TM; Patient navigation (PN) yes or no; repeated offers every 10 or 30 days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TM with or without PN; repeated offers every 10 or 30 days.
Number of subjects: 0
Study: 38508638

Group type: EXPERIMENTAL
Intervention: Occupational physical activity
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Jenkins Sleep Scale
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High occupational physical activity and leisure time physical activity
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: High occupational physical activity and low leisure-time physical activity
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 224
Study: 38508835

Group type: EXPERIMENTAL
Intervention: Givinostat (oral, flexible dose based on weight, twice a day for 72 weeks)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (matching placebo, twice a day for 72 weeks)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Givinostat
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 38508844

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 1347

Group type: COMPARATOR
Intervention: Control therapy (Enalapril or Valsartan)
Number of subjects: 1347
Study: 38508877

Group type: EXPERIMENTAL
Intervention: RAAS blockers
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard treatment (other antihypertensive drugs)
Number of subjects: 88
Study: 38508975

Group type: EXPERIMENTAL
Intervention: Topical diacerein
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical clobetasol
Number of subjects: 0
Study: 38509415

Group type: EXPERIMENTAL
Intervention: Non-invasive blood pressure measurements in patients with AoS
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Logistic regression model for AoS detection
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-invasive blood pressure measurements in patients without AoS
Number of subjects: 149
Study: 38509471

Group type: EXPERIMENTAL
Intervention: MDR (Multidimensional Rehabilitation) programme
Number of subjects: 46

Group type: COMPARATOR
Intervention: HE (Home-based Exercise) programme
Number of subjects: 46
Study: 38509495

Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study: 38509514

Group type: COMPARATOR
Intervention: Supervised exercise without motivational intervention (SUP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Supervised exercise with motivational intervention (SUP+)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unsupervised exercise without motivational intervention (UNSUP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unsupervised exercise with motivational intervention (UNSUP+)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 120
Study: 38509517

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Combination of finerenone with an ACEi or ARB
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 38509583

Group type: EXPERIMENTAL
Intervention: Non-invasive neurally adjusted ventilatory assist (NIV-NAVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-synchronized nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 0
Study: 38509605

Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: SAIA scaled delivery model
Number of subjects: 18
Study: 38509614

Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping (PBCC)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 140
Study: 38509622

Group type: EXPERIMENTAL
Intervention: Clinical risk factors (CRFs)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Proteomics
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Genetic data (GPS)
Number of subjects: 1462
Study: 38509662

Group type: EXPERIMENTAL
Intervention: Smartphone-based speech therapy app for 1 hour per day, 5 days per week, for 4 weeks, with guideline-based standard stroke care.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard guideline-based stroke care and rehabilitation.
Number of subjects: 40
Study: 38509698

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing sleep-disordered breathing (SDB)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing obstructive sleep apnoea (OSA)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing central sleep apnoea (CSA)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: STOP-BANG questionnaire
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) for diagnosing SDB in preserved ejection fraction (EF) CHF
Number of subjects: 116
Study: 38509699

Group type: EXPERIMENTAL
Intervention: Concomitant administration of RV5 and IPV
Number of subjects: 400

Group type: COMPARATOR
Intervention: Staggered administration of RV5 and IPV
Number of subjects: 400
Study: 38510299

Group type: EXPERIMENTAL
Intervention: Asymptomatic CTRCD defined by cTnT greater than the sex-specific 99th percentile URL
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Asymptomatic CTRCD defined by sex-neutral cTnI
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: End of anthracycline therapy
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: CTRCD during adjuvant therapy
Number of subjects: 118
Study: 38510323

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Microfragmented adipose tissue (MFAT)
Number of subjects: 71
Study: 38510483

Group type: EXPERIMENTAL
Intervention: Holographic Memory Resolution® (HMR®)
Number of subjects: 60
Study: 38510502

Group type: EXPERIMENTAL
Intervention: High HDL-C (>70 mg/dL)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Low HDL-C (<50 mg/dL)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Average HDL-C (50-70 mg/dL)
Number of subjects: 607
Study: 38510574

Group type: EXPERIMENTAL
Intervention: mHealth intervention (self-monitored educational intervention via an internet application on mobile devices)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (standard healthcare)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 300
Study: 38510748

Group type: EXPERIMENTAL
Intervention: Culturally relevant gratitude journaling intervention
Number of subjects: 26
Study: 38510979

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules containing polyunsaturated fatty acids (PUFAs) taken once daily for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Soft gelatin capsules containing olive oil (placebo)
Number of subjects: 20
Study: 38510983

Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR) + Nucleos(t)ide Reverse Transcriptase Inhibitors (NrtIs)
Number of subjects: 92
Study: 38511087

Group type: EXPERIMENTAL
Intervention: Subcutaneous Ig20Gly (50-200 mg/kg) administered weekly for 24 weeks (Epoch 2)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Subcutaneous Ig20Gly (100-400 mg/kg) administered every 2 weeks for 12 weeks (Epoch 3)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events during Epochs 2 and 3
Number of subjects: 17
Study: 38511555

Group type: EXPERIMENTAL
Intervention: Patients with CHB after BTI
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy controls (HCs) after BTI
Number of subjects: 101
Study: 38511563

Group type: EXPERIMENTAL
Intervention: Mobocertinib at 160 mg once daily
Number of subjects: 114

Group type: COMPARATOR
Intervention: Mobocertinib
Number of subjects: 114
Study: 38512023

Group type: EXPERIMENTAL
Intervention: 4D flow cardiac MRI with late gadolinium enhancement (LGE) in individuals with HCM
Number of subjects: 88

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cox proportional hazard model analysis
Number of subjects: 88
Study: 38512294

Group type: EXPERIMENTAL
Intervention: Gamified Strength Recognition and Quiz
Number of subjects: 0
Study: 38512307

Group type: EXPERIMENTAL
Intervention: Self-directed VEGA Family Violence Education Resources
Number of subjects: 105

Group type: COMPARATOR
Intervention: Workshop VEGA Family Violence Education Resources
Number of subjects: 105
Study: 38512333

Group type: EXPERIMENTAL
Intervention: DiaCert app (intervention group)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 181
Study: 38512336

Group type: EXPERIMENTAL
Intervention: Web-based physical activity promotion intervention consisting of 4 web-based group workshops over 10 weeks, web-based tasks and resources, and a social support chat group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 254
Study: 38512385

Group type: EXPERIMENTAL
Intervention: Hypo-METRICS Smartphone Application
Number of subjects: 0
Study: 38512387

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basal Insulin Switch
Number of subjects: 0
Study: 38512619

Group type: EXPERIMENTAL
Intervention: Risk- and breast density-stratified screening model (biennial DBT, annual DBT, ultrasound, breast MRI based on risk factors)
Number of subjects: 10469

Group type: COMPARATOR
Intervention: Annual digital mammography (DM) screening
Number of subjects: 10469
Study: 38512694

Group type: EXPERIMENTAL
Intervention: Vutrisiran (25 mg subcutaneous injection once every 3 months)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Patisiran (0.3 mg/kg intravenous infusion once every 3 weeks)
Number of subjects: 164

Group type: COMPARATOR
Intervention: External placebo
Number of subjects: 164
Study: 38512706

Group type: EXPERIMENTAL
Intervention: Nonimmersive Virtual Reality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task-Oriented Circuit Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 38512879

Group type: EXPERIMENTAL
Intervention: New passive ankle prosthesis with an articulated ankle joint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard passive prosthesis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both prosthetic types
Number of subjects: 0
Study: 38512931

Group type: EXPERIMENTAL
Intervention: Post-COVID-19 lockdown
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-COVID-19 lockdown
Number of subjects: 0
Study: 38512958

Group type: EXPERIMENTAL
Intervention: Left posterior sacrospinous fixation (SSF)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bilateral posterior sacrospinous fixation (SSF)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bilateral posterior SSF with suture at 1 cm from ischial spine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Bilateral posterior SSF with suture at 3 cm from ischial spine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Left SSF with suture at 1 cm from ischial spine
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Left SSF with suture at 3 cm from ischial spine
Number of subjects: 1
Study: 38512960

Group type: COMPARATOR
Intervention: Delta variant infection (after 2 doses)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5 infection (after 3 doses)
Number of subjects: 491

Group type: COMPARATOR
Intervention: Delta variant infection
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Omicron BA.4/5 infection
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Omicron sub-variants infections
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: PCR Ct values in BA.1 infections
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Viral load trajectories and peaks
Number of subjects: 491
Study: 38513060

Group type: EXPERIMENTAL
Intervention: Inorganic nitrate (12 mmol potassium nitrate once daily for 5 days)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo (potassium chloride)
Number of subjects: 640
Study: 38513170

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor-based therapy
Number of subjects: 625

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 625
Study: 38513188

Group type: COMPARATOR
Intervention: Fulvestrant (F)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Palbociclib (F + P)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Palbociclib and Avelumab (F + P + A)
Number of subjects: 220
Study: 38513321

Group type: EXPERIMENTAL
Intervention: Cumulative systolic blood pressure (SBP)
Number of subjects: 8282

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 8282

Group type: EXPERIMENTAL
Intervention: Conventional risk factors combined with cumulative SBP
Number of subjects: 8282

Group type: EXPERIMENTAL
Intervention: Cumulative blood pressure (BP)
Number of subjects: 8282

Group type: EXPERIMENTAL
Intervention: Cumulative pulse pressure
Number of subjects: 8282
Study: 38513367

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) combining rowing and cycling for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (sedentary obese and lean individuals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIIT (all groups)
Number of subjects: 0
Study: 38513368

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (100-µg doses)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (after dose 2)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (after dose 3)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (post-additional dose)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (in kidney SOTRs)
Number of subjects: 234
Study: 38513424

Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (5 sessions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (2 sessions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (1 session)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Neurofeedback sessions (3 sessions)
Number of subjects: 15
Study: 38513436

Group type: EXPERIMENTAL
Intervention: Alirocumab (150 mg biweekly)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both groups (Alirocumab and Placebo)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Alirocumab and Placebo
Number of subjects: 139
Study: 38513683

Group type: EXPERIMENTAL
Intervention: MRI-guided stereotactic ablative body radiotherapy (SABR) - five fractions of 8 Gy delivered on non-consecutive days
Number of subjects: 68

Group type: COMPARATOR
Intervention: CT-guided percutaneous irreversible electroporation
Number of subjects: 68
Study: 38513684

Group type: EXPERIMENTAL
Intervention: Co-administered Na-GST-1 on Alhydrogel plus Na-APR-1(M74) on Alhydrogel and glucopyranosyl lipid A in aqueous formulation (GLA-AF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Co-administered ENGERIX-B hepatitis B vaccine (HBV) and saline placebo
Number of subjects: 60
Study: 38513689

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50 µg) booster vaccination and QIV co-administered (Coad group)
Number of subjects: 498

Group type: COMPARATOR
Intervention: mRNA-1273 (50 µg) booster vaccination and QIV sequentially administered (Seq group)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Both groups (Coad and Seq)
Number of subjects: 498
Study: 38513746

Group type: EXPERIMENTAL
Intervention: Motion style acupuncture treatment (MSAT) combined with integrative Korean medicine (IKM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (IKM without MSAT)
Number of subjects: 96
Study: 38513888

Group type: EXPERIMENTAL
Intervention: ω-3 FA supplement (DHA 0.8 g and EPA 1.7 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38513982

Group type: EXPERIMENTAL
Intervention: 3-MDM panel algorithm
Number of subjects: 125
Study: 38514081

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pathologic assessments of PD-L1 status
Number of subjects: 0
Study: 38514101

Group type: EXPERIMENTAL
Intervention: Near-infrared angiography using indocyanine green and endoscopic fluorescence imaging
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard intra-operative assessment (control arm)
Number of subjects: 310
Study: 38514147

Group type: EXPERIMENTAL
Intervention: Pancreatic endotherapy or surgery for clearance of painful pancreatic duct obstruction
Number of subjects: 150
Study: 38514168

Group type: EXPERIMENTAL
Intervention: simplified rPAP respiratory support system
Number of subjects: 32
Study: 38514306

Group type: EXPERIMENTAL
Intervention: Radiological complete response (CR) at week 9
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Radiological partial response (PR) at week 9
Number of subjects: 362

Group type: COMPARATOR
Intervention: Stable disease (SD) at week 9
Number of subjects: 362
Study: 38514519

Group type: EXPERIMENTAL
Intervention: Aortic global longitudinal strain (AOGLS)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Low AOGLS <4.26%
Number of subjects: 194